Sebastian Kaulitzki / Alamy Stock Photo

Explore our latest content

Biopharma Dealmakers brings together life sciences companies and individuals looking to identify and attract partners and dealmaking opportunities.

Browse Articles

  • News Feature |

    In the first of a new monthly digest, we highlight recent ‘business of science’ articles from Springer Nature research journals, magazines and supplements. This digest looks at the latest drugs approved by the US FDA and a $1bn antibody development deal, peeps into the Chan Zuckerberg Biohub, and offers advice to budding science entrepreneurs.

    • Raveena Bhambra
  • Advertisement Feature |

    By reprogramming the tumor microenvironment Kineta is developing an anti-VISTA immuno-oncology therapy for the treatment of a variety of cancers, including gastric, ovarian, lung and pancreatic cancers.

    • Kineta, Inc.
  • Advertisement Feature |

    Using its MicroRx platform, 4D pharma is pioneering the development of an emerging class of therapeutics known as live biotherapeutic products to treat a range of indications from cancer and respiratory disease to neurodegeneration.

    • 4D Pharma PLC
  • Advertisement Feature |

    Sorrento Therapeutics, Inc. is developing a pipeline of fully human immunotherapies selected from its proprietary G-MAB library. Backed by a platform covering discovery, advanced clinical development, manufacturing and a proven track record of commercialization, it seeks to deliver life-changing therapies.

    • Sorrento Therapeutics
  • Advertisement Feature |

    Biotech company APO-T is developing bispecific T cell engagers (BiTEs) that facilitate the attraction of immune effector cells exclusively to cancer sites by targeting cancer cell antigens known as melanoma-associated antigen A (MAGE-A) proteins.

    • APO-T